These Excision Products Are Different From Those Observed With Earlier Generations Of Antisense.

In the presentation, entitled Precise excision of targeted RNA by third generation antisense (3GA) oligonucleotides, Idera scientists presented data that demonstrated that gene-silencing by 3GAs led to excision sites in the targeted mRNA in the region similar to that observed with siRNA. These excision products are different from those observed with earlier generations of antisense. This presentation also provided a demonstration of 3GAs specificity by showing that the incorporation of a mismatch at the region of excision led to the loss of gene-silencing activity. Depending Upon The Production Process, Titanium May Contain A Small Amount Of Nickel, And Many People Are Actually Allergic To Nickel. | Blog Sadie StewartBased on these studies, the company is also conducting studies to further the potential applications of 3GAs in targeting diseases caused by point mutations. Data from these studies is expected to be presented in the second half of 2016. This presentation is currently available on Ideras website at http://www.iderapharma.com/our-science/key-presentations-and-publications . Our in-depth understanding from our pioneering work in antisense technology along with our insights into the interaction of nucleic acids with Toll-like receptors has allowed us to design this very unique technology platform to fully realize the potential of antisense technology, stated Sudhir Agrawal, D. Phil., President of Research at Idera Pharmaceuticals. We are continuing to conduct preclinical studies with multiple 3GA candidates in house and with our collaborators, with a goal of advancing this technology to clinical development. Previously the company has announced the identification of NLRP3 (NOD-like receptor family, pyrin domain containing protein 3) and DUX4 (Double Homeobox 4) as initial gene targets to advance into IND-enabling activities, which will occur throughout 2016. Potential disease indications related to these targets include, but are not limited to, interstitial cystitis, lupus nephritis, uveitis and facioscapulohumeral muscular dystrophy (FSHD). http://laylawilsonlist.pca-plus.com/2016/08/06/and-that-is-you-may-think-that-home-based-treatment-will-not-be-good-enough-like-a-hospital-or-any-other-clinic-based-treatment/The Company is currently conducting clinical, regulatory and commercial analysis activities and conducting IND-enabling studies with the plan to enter the clinic in 2017 for the first clinical development program. In addition to these activities, over the first half of 2016, Idera generated 3GA compounds for a series of additional gene targets. These will enable the Company to continue to expand its future pipeline opportunities for both internal development as well as partnerships in areas outside of Ideras focus. Additionally, Idera is party to a collaboration and license agreement with GSK to research, develop and commercialize compounds from its 3GA technology for the treatment of undisclosed, selected renal targets. About Ideras Third Generation Antisense Platform (3GA) Ideras proprietary third-generation antisense (3GA) platform technology is focused on silencing the mRNA associated with disease causing genes. Idera has designed 3GA oligonucleotides to overcome specific challenges associated with earlier generation antisense technologies and RNAi technologies. About Idera Pharmaceuticals, Inc. Idera Pharmaceuticals is a clinical-stage biopharmaceutical company developing novel nucleic acid-based therapies for the treatment of certain cancers and rare diseases.

For the original version including any supplementary images or video, visit http://finance.yahoo.com/news/idera-pharmaceuticals-presents-novel-mechanism-110000559.html

It.s generally not associated with any other disease. Retinitis affects the back of the eye. Standardization of uveitis nomenclature for reporting clinical data. White or red blood cells may be observed; layering of white blood cells in the anterior chamber is called hypopyon. Treatment will help ease any eye pain and swelling you may have, but keep your doctor informed about any discomfort or changes in your vision. An eye care professional will usually prescribe steroidal anti-inflammatory medication that can be taken as eye drops, swallowed as a pill, injected around or into the eye, infused into the blood intravenously, or, released into the eye via a capsule that is surgically implanted inside the eye. Left alone, it can turn into serious eyesight troubles, like glaucoma or cataracts . Early detection and treatment are important to reduce the risk of vision loss, which can be permanent.

An.ye.are professional will usually prescribe steroidal anti-inflammatory medication that can be taken as eye drops, swallowed as a pill, injected around or into the eye, infused into the blood intravenously, or, released into the eye via a capsule that is surgically implanted inside the eye. This tiny drug implant Retisert, Bausch+Lomb is surgically implanted in the back of the eye, where it delivers sustained amounts of anti-inflammatory medication for treatment of uveitis. The urea pronounced “You-Vay-Uh” is a layer of the eye made up of three parts. In addition to uveitis treatment, Ozurdex implants also are FDA-approved for the treatment of macular enema following retinal vein occlusion and for treatment for diabetic macular enema in adult patients who are pseudophakic or who are scheduled for cataract surgery . Your doctor may recommend sunglasses because bright light may cause discomfort. After graduating from St. Iridocyclitis presents the same symptoms as iritis, but also includes inflammation in the biliary body . 3 Anywhere from two-thirds to 90% of uveitis cases are anterior in location. Because uveitis often is associated with a viral infection or an autoimmune disease, other conditions need to be discovered and treated as well. Conventionally-treated patients were initially given high doses of prednisone, a corticosteroid medication, for 1 to 4 weeks which were then reduced gradually to low doses whereas locally-treated patients had a capsule that slowly released fluocinolone, another corticosteroid medication, surgically inserted in their affected eyes. Blindness may result from inadequate treatment. shied Dr., MD, face, face William C.

Leave a Reply

Your email address will not be published. Required fields are marked *